VTYX- Ventyx Biosciences, Inc. (“Ventyx”), a clinical-stage biopharmaceutical company focused
on advancing novel oral therapies that address a range of inflammatory diseases with significant
unmet medical need, announced today that it has entered into a stock purchase agreement for
the sale of 11,174,000 shares of its common stock at an offering price of...
